Appendix B: Declarations of interest

B.1 Catherine Smith (Chair)

GDG meeting	Declaration of Interests	Action taken
On appointment 6.5.10	Non-personal pecuniary interest: Our research unit receives research and training funds from a number of pharmaceutical companies that manufacture drugs that are used to treat psoriasis and these include Serono, Wyeth (now Pfizer), Schering-Plough, Janssen-Cilag. As an expert in the field of treatments for psoriasis, I have been an invited speaker at a number of educational symposia that have been sponsored by the companies above. Personal non-pecuniary interest: As chair and author of the guideline on biological therapy in psoriasis, we systematically reviewed the evidence for these interventions and published recommendations based on this systematic review.	Declare and participate
First GDG meeting 20.1.11	Non-personal pecuniary interest: Our research unit receives research and training funds from a number of pharmaceutical companies that manufacture drugs that are used to treat psoriasis and these include Serono, Wyeth (now Pfizer), Schering-Plough, Janssen-Cilag. As an expert in the field of treatments for psoriasis, I have been an invited speaker at a number of educational symposia sponsored by the companies above. I am co-investigator in a number of clinical trials sponsored by: Novartis, Janssen-Cilag, Maruho, Abbott, Centocor, Merck, Abbott Labs., Psoriasis Association, GSTT Charity, British Association of Dermatologists, Schering Plough, Pfizer, Wyeth. I am CI on the folowing research grants (which I administer) but none of these are pharma sponsored: British Skin Foundation - Discovering the genetic basis of Acne Vulgaris; Psoriasis Association - Pharamco-genetic markers of systemic treatment outcomes in patients with severe psoriasis	Declare and participate

GDG meeting	Declaration of Interests	Action taken
	- open; Guy's and St Thomas' Charity - Non-invasive measurement of liver fibrosis. Personal non-pecuniary interest: As chair and first author of the guideline on biological therapy in psoriasis, we systematically reviewed the evidence for these interventions and published recommendations based on this systematic review. I am the Chair of the BAD BIR Steering Committee.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	Non-personal pecuniary interest: Research grant from Galderma for research project investigating genetic basis of acne vulgaris (2 year programme of research). This research project is a collaborative project, set up between Kings College London and Galderma. I am CI on the accrual of the clinical / DNA dataset to be used in the planned Genome Wide Association Study. This part of the project was funded by the British Skin Foundation and supported by the NIHR comprehensive research network. The funding to perform the genetic analysis is being provided by Galderma. Professor Richard Trembath is the lead investigator on this part of the project I am co-investigator. I have no direct fiscal responsibility or authority over the monies provided by Galderma.	Declare and participate
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	Non-personal pecuniary interest: I have been invited to give a lecture at a biologics update meeting. The meeting is funded by a pharmaceutical company. There is no personal pecuniary interest; the pharamceutical company provides funding for research staff at St John's Institute, part of King's College , london. My contract of employment is with Guy's and St Thomas' NHS Trust and I also work at St	Declare and participate

GDG meeting	Declaration of Interests	Action taken
	John's Institute.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12	No change to declarations of interest.	

B.2 Christine Bundy

GDG meeting	Declaration of Interests	Action taken
On appointment	Personal pecuniary interest: I hold a Scientific Advisory Board position with	No action necessary.

GDG meeting	Declaration of Interests	Action taken
5.10.10	Simple Healthcare Products for which I receive an honorarium for attending approximately three meetings per year.	
First GDG meeting 20.1.11	Personal pecuniary interest: membership of Educational Advisory Board funded by Abbott. Personal non-pecuniary interest: I have conducted a research project on psoriasis that was funded by PAPAA (Psoriasis and Psoriatic Arthritis Alliance charity).	Withdraw from discussing evidence and formulating recommendations for biologics.
Second GDG Meeting 17.2.11	Personal pecuniary interest: I am an expert advisor to Abbott specialist education advisory group for which I receive a fee. This is involved with establishing education and training support for Dermatology specialist clinicians in the areas of psychological aspects of psoriasis. I hold a Scientific Advisory Board position with Simple Healthcare Products for which I receive an honorarium for attending approximately three meetings per year.	Withdraw from discussing evidence and formulating recommendations for biologics.
Third GDG Meeting 17.3.11	No change to declared interests.	
Fourth GDG meeting 12.4.11	Personal pecuniary interest: I hold a Scientific Advisory Board position with Simple Healthcare Products for which I receive an honorarium for attending approximately three meetings per year. I have been invited onto a medical education steering group to address the skills of clinicians working in Dermatology to detect and manage psychological problems in patients. I will receive an honorarium for attending meetings to develop learning materials from Abbott pharmaceuticals who fund but do not directly input to the project. Pfizer pharmaceuticals have joint funded with the MRC a PhD studentship within the University and I am the lead supervisor on that project.	Withdraw from discussing evidence and formulating recommendations for biologics.
Fifth GDG meeting	No change to declared interests.	

GDG meeting	Declaration of Interests	Action taken
20.5.11		
Sixth GDG meeting 13.7.11	No change to declared interests.	
Seventh GDG meeting 6.9.11	No change to declared interests.	
Eighth GDG meeting 10.10.11	Non-personal pecuniary interest: I have conducted CBT trial having received charitable funding for the research (PAPAA).	Declare and participate.
Ninth GDG meeting 11.10.11	No change to declared interests.	
Tenth GDG meeting 4.11.11	No change to declared interests.	
Eleventh GDG meeting 1.12.11	No change to declared interests.	
Twelfth GDG meeting 23.1.12	No change to declared interests.	
Thirteenth GDG meeting 17.2.12	No change to declared interests.	
Fourteenth GDG meeting 26.7.12		

B.3 David Chandler

GDG meeting	Declaration of Interests	Action taken
On appointment	No interests declared.	No action necessary.

GDG meeting	Declaration of Interests	Action taken
15.9.10		
First GDG meeting 20.1.11	No interests declared.	
Second GDG Meeting 17.2.11	No interests declared.	
Third GDG Meeting 17.3.11	No interests declared.	
Fourth GDG meeting 12.4.11	No interests declared.	
Fifth GDG meeting 20.5.11	No interests declared.	
Sixth GDG meeting 13.7.11	No interests declared.	
Seventh GDG meeting 6.9.11	No interests declared.	
Eighth GDG meeting 10.10.11	No interests declared.	
Ninth GDG meeting 11.10.11	No interests declared.	
Tenth GDG meeting 4.11.11	No interests declared.	

GDG meeting	Declaration of Interests	Action taken
Eleventh GDG meeting 1.12.11	No interests declared.	
Twelfth GDG meeting 23.1.12	No interests declared.	
Thirteenth GDG meeting 17.2.12	No interests declared.	
Fourteenth GDG meeting 26.7.12	No interests declared.	

B.4 James Ferguson

GDG meeting	Declaration of Interests	Action taken
On appointment 12.10.10	Personal pecuniary interest: Director of Ambicare Ltd., - Co-founder / Co-investigator of a light emitting device used in the treatment of skin cancer (but not psoriasis). Director of Spectratox Ltd. - Drug-induced phototoxicity, randomised controlled trials (CRO - charity owned) (also not related to psoriasis).	Declare and participate
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
meeting 12.4.11		
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.5 Paul Hepple

GDG meeting	Declaration of Interests	Action taken
On appointment 23.11.10	None declared.	No action needed.
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
meeting 4.11.11		
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12	No change to declarations of interest.	

B.6 Karina Jackson

GDG meeting	Declaration of Interests	Action taken
On appointment 1.10.10	Personal pecuniary interest: Consultancy work on Abbott educational advisory board. Non-personal pecuniary interest: Unrestricted grant from Abbott laboratories Ltd to support nurse observer visits (preceptorship programme) to St John's Institute of Dermatology.	Withdraw from discussing the evidence and formulating recommendations for biologics until December 2011.
First GDG meeting 20.1.11		
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
meeting 12.4.11		
Fifth GDG meeting 20.5.11	Non-personal pecuniary interest: I have been invited to give a lecture at a biologics update meeting on 19.9.11. The meeting is funded by a pharmaceutical company. There is no personal pecuniary interest; the pharmaceutical company provides funding for research staff at St John's Institute, part of King's College London. My contract of employment is with Guy's and St Thomas' NHS Trust.	No change to action previously agreed in relation to biologics.
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting		

GDG meeting	Declaration of Interests	Action taken
26.7.12		

B.7 Neil McHugh

GDG meeting	Declaration of Interests	Action taken
On appointment 7.10.10	Personal pecuniary interest: I have received payment for membership of advisory group panels for Abbott Laboratories (October 2010) and Schering-Plough (June 2010). Non personal pecuniary interest: My research team have received investigator initiated unrestricted research grants from Abbott Laboratories.	Withdraw from discussing the evidence and making recommendations for biologics.
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
6.9.11		
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.8 Ruth Murphy

GDG meeting	Declaration of Interests	Action taken
On appointment 20.1.11	Personal pecuniary interest: in the last 2 years I have accepted a fee for non-promotional educational lectures about psoriasis from Abbott (July 2010) and Janssen-Cilag (December 2010). I have received sponsorship by way of registration fees, accomodation and standard class travel to attend the American Academy of Dermatology x1 (March 2010) and the British Association of Dermatology x1 (July 2010), European Academy of Dermatology and venerology	Withdraw from discussions and formulating recommendations on biologics until December 2011.

GDG meeting	Declaration of Interests	Action taken
	x1 (October 2010) Wyeth Pfizer, Abbott, Janssen-Cilag.	
First GDG meeting 20.1.11	Personal pecuniary interest: I am the principal investigator for the TRANSIT trial in Nottingham commencing January 2010 ending July 2011.	No action necessary.
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.9 Jillian Peters

GDG meeting	Declaration of Interests	Action taken
On appointment 20.1.11	Non-personal pecuniary interest: Member of the Oversight committee of the All Party Parliamentary group on skin.	No action necessary.
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.10 Natasha Smeaton

GDG meeting	Declaration of Interests	Action taken

GDG meeting	Declaration of Interests	Action taken
On appointment 17.12.10	No interests declared.	
First GDG meeting 20.1.11	Personal family interest: sister is NHS consultant in dermatology based at Newport Hospital.	No action necessary.
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
4.11.11		
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.11 Claire Strudwicke

GDG meeting	Declaration of Interests	Action taken
On appointment 1.10.10	No interests declared.	
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	Personal non-pecuniary interest: Trustee of the Psoriasis Association (expenses received only).	Declare and participate.
Fourth GDG meeting	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
12.4.11		
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.12 Roderick Tucker

GDG meeting	Declaration of Interests	Action taken
On appointment 4.12.10	Personal pecuniary interest: I have given lectures on medicine use reviews for pharmacists and lectures on primary care management of psoriasis supported by Leo Pharma.	Withdraw from discussing the evidence and making recommendations for vitamin D analogues and combined formulations of vitamin D analogies and potent corticosteroids.
First GDG meeting 20.1.11	No change to declarations of interest.	
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	Personal pecuniary interest: I have received a grant from Reckitts Benkiser (who make the emollient E45) which has the following aims: 1) to produce a prototype pharmacist-delivered educational intervention aimed at parents of children with eczema; 2) to delineate the stpes required to deliver the educational intervention; 3) to pilot the feasability of identifying, recruiting and following up patient participants. The money has been paid directly to me (£15,000) of which £8,500 is for my time commitment (one day/week for 12 months) and the rest is to be paid to the university of Leeds where I will be collaborating with two researchers. I am in the process of drawing up a sub-contract (from the university) between the university and myself for the study.	No action necessary.
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	No change to declarations of interest.	
Sixth GDG meeting	No change to declarations of interest.	

GDG meeting	Declaration of Interests	Action taken
13.7.11		
Seventh GDG meeting 6.9.11	No change to declarations of interest.	
Eighth GDG meeting 10.10.11	No change to declarations of interest.	
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	No change to declarations of interest.	
Fourteenth GDG meeting 26.7.12		

B.13 Richard Warren

GDG meeting	Declaration of Interests	Action taken
On appointment 15.10.10	Personal pecuniary interest: I have received from Abbott Pharma, Wyeth (now Pfizer), Schering Plough (now MSD), Janssen Cilag and Leo Pharma for talks and / or consultancy work. All of these companies are involved in the production of therapies for psoriasis. Non-personal	Withdraw from discussing the evidence and formulating recommendations for biologics.

GDG meeting	Declaration of Interests	Action taken
	pecuniary interest: I have been the joint applicant on a successful PhD studentship which will be funded by Abbott Pharma. The work undertaken on the PhD is a basic science PhD related to psoriasis.	
First GDG meeting 20.1.11	Personal pecuniary interest: In the last 6 years I have been a consultant for Abbott, Schering Plough (now MSD), Wyeth (now Pfizer), Leo (now Jannsen Cilag) and a paid speaker for Leo (now Jannsen Cilag), Abbot, Pfizer and Schering Ploug. Personal non-pecuniary interest: Funding for a PhD student: Abbott and Funding from a PhD student: Leo	Withdraw from discussing the evidence and formulating recommendations for biologics and vitamin D analogues / combined preparation of vitamin D analogue and potent corticosteroid.
Second GDG Meeting 17.2.11	No change to declarations of interest.	
Third GDG Meeting 17.3.11	No change to declarations of interest.	
Fourth GDG meeting 12.4.11	No change to declarations of interest.	
Fifth GDG meeting 20.5.11	Personal pecuniary interest: Phase 4 clinical trial involving Dovobet versus Dovobet and enhanced education input and support to assess compliance of the two regimens. Run by the University of Hamburg and supported by an unrestricted grant from Leo (CIs -Professor Reich and Mroweiz) with me as UK PI. To run over 1 252 week period starting in Autumn 2011.	Withdraw from discussing the evidence and formulating recommendations for vitamin D analogues / combined preparation of vitamin D analogue and potent corticosteroid.
Sixth GDG meeting 13.7.11	No change to declarations of interest.	
Seventh GDG meeting 6.9.11	Personal pecuniary interest: I am being a paid speaker at world summit of psoriasis in Buenos Aires on 30th August 2011. This event is funded by Abbott, a manufacturer	Withdraw from discussing the evidence and formulating recommendations for biologics.

GDG meeting	Declaration of Interests	Action taken
	of a biologic agent.	
Eighth GDG meeting 10.10.11	Personal pecuniary interest: I have been asked to take part in an initiative related to the transitioning of biologic therapies run by Abbott on October 27th.	Withdraw from discussing the evidence and formulating recommendations for biologics.
Ninth GDG meeting 11.10.11	No change to declarations of interest.	
Tenth GDG meeting 4.11.11	No change to declarations of interest.	
Eleventh GDG meeting 1.12.11	No change to declarations of interest.	
Twelfth GDG meeting 23.1.12	No change to declarations of interest.	
Thirteenth GDG meeting 17.2.12	Personal pecuniary interest: January 2012: Involved in psoriasis progressive initiative run by Abbott. Meeting takes place in January 2012 but the project is ongoing with potentially more meetings in the future. February 2012: Invited to speak in Dublin at an event sponsored by Janssen. February 2012: sitting on an advisory board run by Abbott.	Withdraw from discussing the evidence and formulating recommendations for biologics.
Fourteenth GDG meeting 26.7.12	Declared on 27.4.12: I have been asked to do Abbotts symposium at the annual BAD meeting in July – Birmingham	